Anthrax: An update

Asian Pacific Journal of Tropical Biomedicine

Volumn 1, Issue 6, 2011, Pages 496-501

  Kamal, S M ^a   Rashid, AKM M ^a   Bakar, M A ^a   Ahad, M A ^a  

^a Khulna Medical College   (Bangladesh)

Author keywords

Anthrax; Bacillus anthracis; Contagious disease; Cutaneous anthrax; Gastrointestinal anthrax; Human anthrax; Inhalational anthrax; Zoonotic disease

Indexed keywords

ANTHRAX VACCINE; ANTIBIOTIC AGENT; CIPROFLOXACIN; CORTICOSTEROID; CPG OLIGODEOXYNUCLEOTIDE; DALBAVANCIN; DOXYCYCLINE; PENICILLIN G; PENICILLIN V; STREPTOMYCIN; ANTIINFECTIVE AGENT; BIOLOGICAL WARFARE AGENT;

ADJUVANT THERAPY; ANTHRAX; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL TRANSMISSION; BACTERIUM EXAMINATION; CLINICAL FEATURE; CUTANEOUS ANTHRAX; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; GASTROINTESTINAL ANTHRAX; HUMAN; INFECTION PREVENTION; INHALATIONAL ANTHRAX; NONHUMAN; PRIORITY JOURNAL; SEROLOGY; SINGLE DRUG DOSE; SKIN SURGERY; UNSPECIFIED SIDE EFFECT; ANIMAL; BIOLOGICAL WARFARE AGENT; DRUG EFFECTS; HEALTH; INCIDENCE; MICROBIOLOGY; PATHOLOGY; PHYSIOLOGY; VETERINARY; ZOONOSES;

ANIMALS; ANTHRAX; ANTI-BACTERIAL AGENTS; BACILLUS ANTHRACIS; BIOLOGICAL WARFARE AGENTS; GLOBAL HEALTH; HUMANS; INCIDENCE; ZOONOSES;

EID: 83655182615     PISSN: 22211691     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2221-1691(11)60109-3     Document Type: Article

References (27)

1. Stembach G The history of anthrax. J Emerg Med 2003, 24:463-467.
2. Dixon IC, Mesclson M, Guillemin J, Hanna PC Anthrax. N Engl J Med 1999, 341:815-826.
3. Mandell GL, Bennett JE, Dolin R Principles and practice of infectious disease 2000, 2215-2220. Churchill Livingstone Inc, Philadelphia. 5th ed.
4. Babamahmoodi F, Aghabarari F, Arjmand A, Ashrafi GH Three rare cases of anthrax arising from the same source. J Infect 2006, 53:175-179.
5. Jernigan JA, Stephens DS, Ashford DA, Omenaca C, Topiel MS, Galbraith M, et al. Bioterrorism related inhalational anthrax the first 10 cases reported in the United States. Emerg Infect Dis 2001, 7:933-944.
6. Morris K US military face punishment for refusing anthrax vaccine. Lancet 1999, 353:130.
7. Brachman PS Bioterrorism: an update with a focus on anthrax. Am J Epidemiol 2002, 155:981-987.
8. Jamie WE Anthrax: diagnosis, treatment, prevention. Prim Care Update Ob Gyns 2002, 9:117-121.
9. Swartz M Recognition and management of anthrax: an update. Current concepts. N Engl J Med 2001, 345:1621-1626.
10. Inlesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Friedlander AM, et al. Anthrax as a biological weapon: medical and public health management. JAMA 1999, 281:1735-1745.
11. Brook I The prophylaxis and treatment of anthrax. Int J Antimicrob Agents 2002, 20:320-325.
12. Haas CN On the risk of mortality to primates exposed to anthrax spores. Risk Anal 2002, 22:189-193.
13. Dixon IC, Mesclson M, Guillemin J, Hanna PC Anthrax. N Engl J Med 1999, 341:818-826.
14. Broak I, Elliott IB In vitro resistance of Bacillus anthracis to doxicyclin, macrolides and quinolones. Int J Antimicrob Agents 2001, 18:559-562.
15. Centre for Disease Control and Prevention Additional options for preventive treatment for persons exposed to inhalational anthrax. MMWR Wkly Rep 2001, 50:1142-1151.
16. Centre for Disease Control and Prevention Interim guidelines for investigation of and response to Bacillus anthracis exposure. MMWR Morb Mortal Wkly Rep 2001, 50:987-990.
17. Streit JM, Fritsche TR, Sader HS, Jones RN World wide assessment of dalbavancin activity and spectrum against over 6000 clinical isolates. Diagn Microbiol Infect Dis 2004, 48:137-143.
18. Leighton A, Gattlieb AB, Dorrr MB, Jabes D, Moscooni G, Vansaders C, et al. Tolerability, pharmacokinetics and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother 2004, 48:940-945.
19. Klinmon DM, Tross D A single dose combination therapy that both prevents and treats anthrax infection. Vaccine 2009, 27:1811-1815.
20. Vietri NJ, Purcell BK, Lawler JV, Leffel EK, Rico P, Gamble CS, et al. Short course post exposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax. Proc Natl Acad Sci USA 2006, 103:7813-7816.
21. Karginov VA, Robinson TM, Riemenschneider J, Golding B, Kennedy M, Shiloach J, et al. Treatment of anthrax infection with combination of ciprofloxacin and antibodies to protective antigen of Bacillus anthracis. FEMS Immunol Med Microbiol 2004, 40:71-74.
22. Vitale L, Blanset D, Lowy I, O' Neill I, Goldstein J, Little SF, et al. Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine induced immunity. Infect Immun 2006, 74:5840-5847.
23. Food and Drug Administration Prescription drug products, doxiycline and penicillin G procaine administration for inhalational anthrax (Post exposure). Fed Reg 2001, 66:55679-55682.
24. Centre for Disease Control and Prevention Use of anthrax vaccine in the United States recommendations of the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep 2000, 15:12-14.
25. Inglesby TV, O' Toole P, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, et al. Anthrax as a biological weapon, 2002 update recommendations for management. J Am Med Assoc 2002, 287:2236-2252.
26. Ashford DA, Rotz LD, Perkins B Use of anthrax vaccine in the United States. Recommendations of the advisory committee on immunization practices. MMWR 2000, 49:15.
27. Moran G, Talan D, Pinner R CDC update: update on emerging infections from the centre for disease control and prevention. Bioterrorism alleging use of anthrax and interim guidelines from management-United States, 1998. Ann Emerg Med 1999, 34:69-74.